CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia

被引：0
|
作者：
Jing, P. [1 ,2 ]
Niu, Q. [2 ]
Deng, B. [3 ]
Liu, S. [1 ]
Wu, T. [4 ]
Gao, Z. [4 ]
Chang, A. H. [5 ]
Feng, X. [2 ]
Tong, C. [1 ]
机构：
[1] Beijing Boren Hosp, Dept Hematol, Beijing, Peoples R China
[2] Inst Hematol & Hosp Blood Dis, Tianjin, Peoples R China
[3] Beijing Boren Hosp, Cytol Lab, Beijing, Peoples R China
[4] Beijing Boren Hosp, Dept Bone Marrow Transplantat, Beijing, Peoples R China
[5] Tongji Univ, Sch Med, Clin Translat Res Ctr, Shanghai, Peoples R China
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2019年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P2287
引用
收藏
页码：1723 / 1723
页数：1
相关论文
共 50 条
  • [31] Use of CD19-directed CAR T-Cell Therapy in an Infant With Refractory Acute Lymphoblastic Leukemia
    Breese, Erin H.
    Krupski, Christa
    Nelson, Adam S.
    Perentesis, John P.
    Phillips, Christine L.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2021, 43 (04) : 152 - 154
  • [32] CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study
    Wei, Guoqing
    Zhang, Yanlei
    Zhao, Houli
    Wang, Yiyun
    Liu, Yandan
    Liang, Bin
    Wang, Xiujian
    Xu, Huijun
    Cui, Jiazhen
    Wu, Wenjun
    Zhao, Kui
    Nagler, Arnon
    Chang, Alex H.
    Hu, Yongxian
    Huang, He
    CANCER IMMUNOLOGY RESEARCH, 2021, 9 (09) : 1061 - 1070
  • [33] NELARABINE IN CHILDREN WITH REFRACTORY AND RELAPSED T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
    Myakova, N.
    Diakonova, Y.
    Bydanov, O.
    Ponomareva, N.
    Fechina, L.
    Boychenko, E.
    Karachunsky, A.
    Shamardina, A.
    HAEMATOLOGICA, 2015, 100 : 349 - 349
  • [34] Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
    Zhang, Xian
    Yang, Junfang
    Li, Wenqian
    Zhang, Gailing
    Su, Yunchao
    Shi, Yanze
    Song, Dan
    Zhang, Min
    He, Jiujiang
    Xu, Li
    Li, Jingjing
    Lu, Xinan
    Li, Jianqiang
    Li, Xiangqun
    Xu, Zhongwei
    Li, Ziyu
    Lu, Peihua
    BLOOD, 2020, 136
  • [35] Anti-CD19 CAR T-cell therapy post antibody treatment in adult patients with relapsed/refractory precursor B-acute lymphoblastic leukemia
    Danylesko, Ivetta
    Besser, Michal
    Jacoby, Elad
    Itzhaki, Orit
    Shem-Tov, Noga
    Yerushalmi, Ronit
    Toren, Amos
    Shimoni, Avichai
    Nagler, Arnon
    Avigdor, Abraham
    BONE MARROW TRANSPLANTATION, 2019, 54 : 517 - 518
  • [36] Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy
    Huang, Jie
    Rong, Liucheng
    Wang, Enxiu
    Fang, Yongjun
    IMMUNOTHERAPY, 2021, 13 (01) : 5 - 10
  • [37] CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease
    Pehlivan, Katherine C.
    Duncan, Brynn B.
    Lee, Daniel W.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2018, 13 (05) : 396 - 406
  • [38] CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease
    Katherine C. Pehlivan
    Brynn B. Duncan
    Daniel W. Lee
    Current Hematologic Malignancy Reports, 2018, 13 : 396 - 406
  • [39] Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia
    Yurkiewicz, Ilana R.
    Muffly, Lori
    Liedtke, Michaela
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 2293 - 2300
  • [40] Sequential treatment with anti-CD19 and CD22 chimeric antigen receptor T cells in children with relapsed or refractory B acute lymphoblastic leukemia
    Chanut, Mathilde
    HEMATOLOGIE, 2023, 29 (06): : 332 - 334
12345